Targeting FoxO1 for hypertriglyceridemia

Current Drug Targets

Volumn 12, Issue 9, 2011, Pages 1245-1255

  Kim, Dae Hyun ^a   Zhang, Ting ^a   Ringquist, Steven ^a   Dong, H Henry ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

FoxO1; Hypertriglyceridemia; Insulin resistance; Type 2 diabetes

Indexed keywords

SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FKHR;

ACETYLATION; CELL DIFFERENTIATION; CELL PROLIFERATION; DEACETYLATION; DRUG CONJUGATION; ENZYME ACTIVITY; GENE DELIVERY SYSTEM; GENE SILENCING; GLUCOSE METABOLISM; GLYCOSYLATION; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN LIKE ACTIVITY; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; METHYLATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN DEGRADATION; REVIEW; TRANSCRIPTION REGULATION; UBIQUITINATION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIVER; OBESITY;

EID: 79959988974     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011796150262     Document Type: Review

References (127)

1. Knopp RH, Retzlaff B, Aikawa K, Kahn SE. Management of patients with diabetic hyperlipidemia. Am J Cardiol 2003; 91: 24E-28E.
2. Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 2004; 117: 421-426.
3. Barthel A, Schmoll D, Unterman TG. FoxO proteins in insulin action and metabolism. Trends Endocrinol Metab 2005; 16: 183-189.
4. Kamagate A, Dong HH. FoxO1 integrates insulin signaling to VLDL production. Cell Cycle 2008; 7: 3162-3170.
5. Sparks DJ, Dong HH. FoxO1 and hepatic lipid metabolism. Curr Opin Lipidol 2009; 20: 217-226.
6. Lee SS, Kennedy S, Tolonen AC, Ruvkun G. DAF-16 target genes that control C. elegans life-span and metabolism. Science 2003; 300: 644-647.
7. Hwangbo DS, Gershman B, Tu MP, Palmer M, Tatar M. Drosophila dFOXO controls lifespan and regulates insulin signalling in brain and fat body. Nature 2004; 429: 562-566.
8. Dong XC, Copps KD, Guo S, et al. Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab 2008; 8: 65-76.
9. Arden KC. FoxO: linking new signaling pathways. Mol Cell 2004; 14: 416-418.
10. van der Heide LP, Jacobs FM, Burbach JP, Hoekman MM, Smidt MP. FoxO6 transcriptional activity is regulated by Thr26 and Ser184, independent of nucleo-cytoplasmic shuttling. Biochem J 2005; 391: 623-629.
11. Rena G, Prescott AR, Guo S, Cohen P, Unterman TG. Roles of the forkhead in rhabdomyosarcoma (FKHR) phosphorylation sites in regulating 14-3-3 binding, transactivation and nuclear targetting. Biochem J 2001; 354: 605-612.
12. Woods YL, Rena G. Effect of multiple phosphorylation events on the transcription factors FKHR, FKHRL1 and AFX. Biochem Soc Trans 2002; 30: 391-397.
13. Van Der Heide LP, Hoekman MF, Smidt MP. The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J 2004; 380: 297-309.
14. Tsai WC, Bhattacharyya N, Han LY, Hanover JA, Rechler MM. Insulin inhibition of transcription stimulated by the forkhead protein Foxo1 is not solely due to nuclear exclusion. Endocrinology 2003; 144: 5615-5622.
15. Zhang X, Gan L, Pan H, et al. Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1) by multiple mechanisms. Direct and indirect effects on nuclear/cytoplasmic shuttling and DNA binding. J Biol Chem 2002; 277: 45276-45284.
16. Jacobs FM, van der Heide LP, Wijchers PJ, et al. FoxO6, a novel member of the FoxO class of transcription factors with distinct shuttling dynamics. J Biol Chem 2003; 278: 35959-35967.
17. Cahill CM, Tzivion G, Nasrin N, et al. Phosphatidylinositol 3-kinase signaling inhibits DAF-16 DNA binding and function via 14-3-3-dependent and 14-3-3-independent pathways. J Biol Chem 2001; 276: 13402-13410.
18. Zhao X, Gan L, Pan H, et al. Multiple elements regulate nuclear/cytoplasmic shuttling of FOXO1: characterization of phosphorylation-and 14-3-3-dependent and -independent mechanisms. Biochem J 2004; 378: 839-849.
19. Silhan J, Vacha P, Strnadova P, et al. 14-3-3 protein masks the DNA binding interface of forkhead transcription factor FOXO4. J Biol Chem 2009; 284: 19349-19360.
20. Bridges D, Moorhead GB. 14-3-3 proteins: a number of functions for a numbered protein. Sci STKE 2004; 2004: re10.
21. Brunet A, Kanai F, Stehn J, et al. 14-3-3 transits to the nucleus and participates in dynamic nucleoctyoplasmic transport. J Cell Biol 2001; 156: 817-828.
22. Nakae J, Barr V, Accili D. Differential regulation of gene expression by insulin and IGF-1 receptors correlates with phosphorylation of a single amino acid residue in the forkhead transcription factor FKHR. EMBO J 2000; 19: 989-996.
23. Tomizawa M, Kumar A, Perrot V, et al. Insulin inhibits the activation of transcription by a C-terminal fragment of the forkhead transcription factor FKHR. J Biol Chem 2000; 275: 7289-7295.
24. Nakae J, Kitamura T, Silver DL, Accili D. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J Clin Invest 2001; 108: 1359-1367.
25. Granner D, Pilkis S. The genes of hepatic glucose metabolism. J Biol Chem 1990; 265: 10173-10176.
26. O'Brien RM, Granner DK. Regulation of gene expression by insulin. Physiol Rev 1996; 76: 1109-1161.
27. Durham SK, Suwanichkul A, Scheimann AO, et al. FKHR binds the insulin response element in the insulin-like growth factor binding protein-1 promoter. Endocrinology 1999; 140: 3140-3146.
28. O'Brien RM, Lucas PC, Forest CD, Magnuson MA, Granner DK. Identification of a sequence in the PEPCK gene that medites a negative effect of insulin on transcription. Science 1990; 249: 533-537.
29. Ayala JE, Streeper RS, Desgrosellier JS, et al. Conservation of an insulin response unit between mouse and human glucose-6-phosphatase catalytic subunit gene promoters. Diabetes 1999; 48:1885-1889.
30. Altomonte J, Cong L, Harbaran S, et al. Foxo1 mediates insulin action on ApoC-III and triglyceride metabolism. J Clin Invest 2004; 114: 1493-1503.
31. Altomonte J, Richter A, Harbaran S, et al. Inhibition of Foxo1 Function Is Associated with Improved Fasting Glycemia in Diabetic Mice. Am J Physiol 2003; 285: E718-E728.
32. Qu S, Altomonte J, Perdomo G, et al. Aberrant Forkhead box O1 function is associated with impaired hepatic metabolism. Endocrinology 2006; 147: 5641-5652.
33. Kamagate A, Qu S, Perdomo G, et al. FoxO1 mediates insulindependent regulation of hepatic VLDL production in mice. J Clin Invest 2008; 118: 2347-2364.
34. Barthel A, Schmoll S, Kruger K-D, et al. Differential regulation of endogenous glucose-6-phosphatase and phosphoenolpyruvate carboxykinase gene expression by the forkhead transcription factor FKHR in H4IIE-hepatoma cells. Biochem Biophys Res Commun 2001; 285: 897-902.
35. Hall RK, Yamasaki T, Kucera T, et al. Regulation of phosphoenlpyruvate carboxykinase and insulin-like growth factorbinding protein-1 gene expression by insulin. J Biol Chem 2000; 275: 30169-30175.
36. Vander Kooi BT, Streeper RS, Svitek CA, et al. The three insulin response sequences in the glucose-6-phosphatase catalytic subunit gene promoter are functionally distinct. J Biol Chem 2003; 278: 11782-11793.
37. Pilkis SJ, Granner DK. Molecular physiology of the regulation of hepatic gluconeogenesis and glycogenolysis. Annu Rev Physiol 1992; 54: 885-909.
38. Imae M, Fu Z, Yoshida A, Noguchi T, Kato H. Nutritional and hormonal factors control the gene expression of FoxOs, the mammalian homologues of DAF-16. J Mol Endocrinol 2003; 30: 253-262.
39. Altomonte J, Qu S, Meseck M, Dong H. Aberrant Foxo1 expression is associated with intrahepatic fat deposition and impaired insulin action in liver. Diabetes 2005; 54 (suppl 1): p.A334.
40. Shachter NS. Apolipoproteins C-1 and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 2001; 12: 297-304.
41. Wang C, McConathy WJ, Kloer HJ, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins: effect of apolipoprotein C-III. J Clin Invest 1985; 75: 384.
42. Onat A, Hergenc G, Sansoy V, et al. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis 2003; 168: 81-89.
43. Li WW, Dammerman MM, Smith JD, et al. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 1995; 96: 2601-2605.
44. Qu S, Su D, Altomonte J, et al. PPAR{alpha} mediates the hypolipidemic action of fibrates by antagonizing FoxO1. Am J Physiol Endocrinol Metab 2007; 292: E421-E434.
45. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 1995; 95: 158-166.
46. den Boer MA, Voshol PJ, Kuipers F, Romijn JA, Havekes LM. Hepatic glucose production is more sensitive to insulin-mediated inhibition than hepatic VLDL-triglyceride production. Am J Physiol Endocrinol Metab 2006; 291: E1360-E1364.
47. Malmstrom R, Packard CJ, Caslake M, et al. Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. Diabetes 1998; 47: 779-787.
48. Malmstrom R, Packard CJ, Watson TD, et al. Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol 1997; 17: 1454-1464.
49. Lewis GF, Steiner G. Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state. Diabetes Care 1996; 19: 390-393.
50. Sparks JD, Sparks CE. Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochim Biophys Acta 1994; 1215: 9-32.
51. Tietge UJ, Bakillah A, Maugeais C, et al. Hepatic overexpression of microsomal triglyceride transfer protein (MTP) results in increased in vivo secretion of VLDL triglycerides and apolipoprotein B. J Lipid Res 1999; 40: 2134-2139.
52. Jamil H, Chu CH, Dickson JK, Jr, et al. Evidence that microsomal triglyceride transfer protein is limiting in the production of apolipoprotein B-containing lipoproteins in hepatic cells. J Lipid Res 1998; 39: 1448-1454.
53. Hussain MM, Shi J, Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res 2003; 44: 22-32.
54. Berriot-Varoqueaux N, Aggerbeck LP, Samson-Bouma M, Wetterau JR. The role of the microsomal triglygeride transfer protein in abetalipoproteinemia. Annu Rev Nutr 2000; 20: 663-697.
55. Liao W, Hui TY, Young SG, Davis RA. Blocking microsomal triglyceride transfer protein interferes with apoB secretion without causing retention or stress in the ER. J Lipid Res 2003; 44: 978-985.
56. Bjorkegren J, Beigneux A, Bergo MO, Maher JJ, Young SG. Blocking the secretion of hepatic very low density lipoproteins renders the liver more susceptible to toxin-induced injury. J Biol Chem 2002; 277: 5476-5483.
57. Leung GK, Veniant MM, Kim SK, et al. A deficiency of microsomal triglyceride transfer protein reduces apolipoprotein B secretion. J Biol Chem 2000; 275: 7515-7520.
58. Raabe M, Veniant MM, Sullivan MA, et al. Analysis of the role of microsomal triglyceride transfer protein in the liver of tissuespecific knockout mice. J Clin Invest 1999; 103: 1287-1298.
59. Raabe M, Flynn LM, Zlot CH, et al. Knockout of the abetalipoproteinemia gene in mice: reduced lipoprotein secretion in heterozygotes and embryonic lethality in homozygotes. Proc Natl Acad Sci USA 1998; 95: 8686-8691.
60. Chang BH, Liao W, Li L, et al. Liver-specific inactivation of the abetalipoproteinemia gene completely abrogates very low density lipoprotein/low density lipoprotein production in a viable conditional knockout mouse. J Biol Chem 1999; 274: 6051-6055.
61. Bernard S, Touzet S, Personne I, et al. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia 2000; 43: 995-999.
62. Ledmyr H, Karpe F, Lundahl B, et al. Variants of the microsomal triglyceride transfer protein gene are associated with plasma cholesterol levels and body mass index. J Lipid Res 2002; 43: 51-58.
63. Ledmyr H, McMahon AD, Ehrenborg E, et al. The microsomal triglyceride transfer protein gene-493T variant lowers cholesterol but increases the risk of coronary heart disease. Circulation 2004; 109: 2279-2284.
64. Juo SH, Han Z, Smith JD, Colangelo L, Liu K. Common polymorphism in promoter of microsomal triglyceride transfer protein gene influences cholesterol, ApoB, and triglyceride levels in young african american men: results from the coronary artery risk development in young adults (CARDIA) study. Arterioscler Thromb Vasc Biol 2000; 20: 1316-1322.
65. Garcia-Garcia AB, Gonzalez C, Real JT, et al. Influence of microsomal triglyceride transfer protein promoter polymorphism -493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia. Pharmacogenet Genom 2005; 15: 211-218.
66. Sparks JD, Sparks CE. Overindulgence and metabolic syndrome: is FoxO1 a missing link? J Clin Invest 2008; 118: 2012-2015.
67. Zhang L, Perdomo G, Kim DH, et al. Proteomic analysis of fructose-induced fatty liver in hamsters. Metabolism 2008; 57: 1115-1124.
68. Nakae J, Biggs WH, Kitamura T, et al. Regulation of insulin action and pancreatic ß-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat Genet 2002; 32: 245-253.
69. Nakae J, Kitamura T, Kitamura Y, et al. The forkhead transcription factor Foxo1 regulates adipocyte differentiation. Dev Cell 2003; 4: 119-129.
70. Okamoto H, Nakae J, Kitamura T, et al. Transgenic rescue of insulin receptor-deficient mice. J Clin Invest 2004; 114: 214-223.
71. Valenti L, Rametta R, Dongiovanni P, et al. Increased expression and activity of the transcription factor Foxo1 in nonalcoholic steatohepatitis. Diabetes 2008; 57: 1355-1362.
72. Zhang W, Patil S, Chauhan B, et al. FoxO1 Regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. J Biol Chem 2006; 281: 10105-10117.
73. Matsumoto M, Han S, Kitamura T, Accili D. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J Clin Invest 2006; 116: 2464-2472.
74. Samuel VT, Liu ZX, Qu X, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004; 279: 32345-32353.
75. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121.
76. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 3023-3028.
77. Samuel VT, Liu ZX, Wang A, et al. Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest 2007; 117: 739-745.
78. Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009; 106: 15430-15435.
79. Schattenberg JM, Singh R, Wang Y, et al. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 2006; 43: 163-172.
80. Kim JJ, Li P, Huntley J, et al. FoxO1 haploinsufficiency protects against high-fat diet-induced insulin resistance with enhanced peroxisome proliferator-activated receptor gamma activation in adipose tissue. Diabetes 2009; 58: 1275-1282.
81. Altomonte J, Qu S, Dong H. Fibrates Down-regulate Foxo1 expression and ameliorate hypertriglyceridemia in high fructose diet-fed hamsters. Diabetes 2005; 54 (Suppl 1): p. A2.
82. Essers MA, Weijzen S, de Vries-Smits AM, et al. FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. EMBO J 2004; 23: 4802-4812.
83. Motta MC, Divecha N, Lemieux M, et al. Mammalian SIRT1 represses forkhead transcription factors. Cell 2004; 116: 551-563.
84. Brunet A, Sweeney LB, Sturgill JF, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004; 303: 2011-2015.
85. Daitoku H, Hatta M, Matsuzaki H, et al. Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity. Proc Natl Acad Sci USA 2004; 101: 10042-10047.
86. Furukawa-Hibi Y, Kobayashi Y, Chen C, Motoyama N. FOXO transcription factors in cell-cycle regulation and the response to oxidative stress. Antioxid Redox Signal 2005; 7: 752-760.
87. Bordone L, Guarente L. Calorie restriction, SIRT1 and metabolism: understanding longevity. Nat Rev Mol Cell Biol 2005; 6: 298-305.
88. Guarente L, Picard F. Calorie restriction--the SIR2 connection. Cell 2005; 120: 473-482.
89. Frescas D, Valenti L, Accili D. Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. J Biol Chem 2005; 280: 20589-20595.
90. Nakae J, Cao Y, Daitoku H, et al. The LXXLL motif of murine forkhead transcription factor FoxO1 mediates Sirt1-dependent transcriptional activity. J Clin Invest 2006; 116: 2473-2483.
91. van der Heide LP, Smidt MP. Regulation of Fox O activity by CBP/p300-mediated acetylation. Trends Biochem Sci 2005; 30: 81-86.
92. Matsuzaki H, Daitoku H, Hatta M, et al. Acetylation of Foxo1 alters its DNA-binding ability and sensitivity to phosphorylation. Proc Natl Acad Sci USA 2005; 102: 11278-11283.
93. Perrot V, Rechler MM. The coactivator p300 directly acetylates the forkhead transcription factor Foxo1 and stimulates Foxo1-induced transcription. Mol Endocrinol 2005; 19: 2283-2298.
94. Matsuzaki H, Daitoku H, Hatta M, Tanaka K, Fukamizu A. Insulininduced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc Natl Acad Sci USA 2003; 100: 11285-11290.
95. Aoki M, Jiang H, Vogt PK. Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. Proc Natl Acad Sci USA 2004; 101: 13613-13617.
96. Huang H, Regan KM, Wang F, et al. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci USA 2005; 102: 1649-1654.
97. Plas DR, Thompson CB. Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J Biol Chem 2003; 278: 12361-12366.
98. Fu W, Ma Q, Chen L, et al. MDM2 acts downstream of p53 as an E3 ligase to promote FOXO ubiquitination and degradation. J Biol Chem 2009; 284: 13987-4000.
99. Brenkman AB, de Keizer PL, van den Broek NJ, Jochemsen AG, Burgering BM. Mdm2 induces mono-ubiquitination of FOXO4. PLoS One 2008; 3: e2819.
100. Kato S, Ding J, Pisck E, Jhala US, Du K. COP1 functions as a FoxO1 ubiquitin E3 ligase to regulate FoxO1-mediated gene expression. J Biol Chem 2008; 283: 35464-35473.
101. Yan L, Lavin VA, Moser LR, et al. PP2A regulates the proapoptotic activity of FOXO1. J Biol Chem 2008; 283: 7411-7420.
102. Stoica BA, Movsesyan VA, Lea PMT, Faden AI. Ceramide-induced neuronal apoptosis is associated with dephosphorylation of Akt, BAD, FKHR, GSK-3beta, and induction of the mitochondrialdependent intrinsic caspase pathway. Mol Cell Neurosci 2003; 22: 365-382.
103. Yamagata K, Daitoku H, Takahashi Y, et al. Arginine methylation of FOXO transcription factors inhibits their phosphorylation by Akt. Mol Cell 2008; 32: 221-231.
104. Krause CD, Yang ZH, Kim YS, et al. Protein arginine methyltransferases: evolution and assessment of their pharmacological and therapeutic potential. Pharmacol Ther 2007; 113: 50-87.
105. D'Alessandris C, Andreozzi F, Federici M, et al. Increased Oglycosylation of insulin signaling proteins results in their impaired activation and enhanced susceptibility to apoptosis in pancreatic beta-cells. FASEB J 2004; 18: 959-961.
106. Blanquart C, Karouri SE, Issad T. Implication of protein tyrosine phosphatase 1B in MCF-7 cell proliferation and resistance to 4-OH tamoxifen. Biochem Biophys Res Commun 2009; 387: 748-753.
107. Kuo M, Zilberfarb V, Gangneux N, Christeff N, Issad T. OGlcNAc modification of FoxO1 increases its transcriptional activity: a role in the glucotoxicity phenomenon? Biochimie 2008; 90: 679-685.
108. Kuo M, Zilberfarb V, Gangneux N, Christeff N, Issad T. Oglycosylation of FoxO1 increases its transcriptional activity towards the glucose 6-phosphatase gene. FEBS Lett 2008; 582: 829-834.
109. Housley MP, Rodgers JT, Udeshi ND, et al. O-GlcNAc regulates FoxO activation in response to glucose. J Biol Chem 2008; 283: 16283-16292.
110. McConathy WJ, Gesquiere JC, Bass H, Tartar A, Fruchart JC. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res 1992; 33: 995-1003.
111. Kinnunen PKJ, Ehnholm C. Effect of serum and C apolipoproteins from very low density lipoproteins on human post-heparin plasma hepatic lipase. FEBS Lett 1976; 65: 354-357.
112. Samuel VT, Choi CS, Phillips TG, et al. Targeting foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action. Diabetes 2006; 55: 2042-2050.
113. Rozema DB, Lewis DL, Wakefield DH, et al. Dynamic polyconjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci USA 2007; 104: 12982-12987.
114. Wu J, Nantz MH, Zern MA. Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications. Front Biosci 2002; 7: d717-d725.
115. Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006; 441: 111-114.
116. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432: 173-178.
117. Wolfrum C, Shi S, Jayaprakash KN, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 2007; 25: 1149-1157.
118. Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 2008; 105: 11915-11920.
119. Barr FG, Nauta LE, Davis RJ, et al. In vivo amplification of the PAX3-FKHR and PAX7-FKHR fusion genes in alveolar rhabdomyosarcoma. Hum Mol Genet 1996; 5: 15-21.
120. Adachi M, Osawa Y, Uchinami H, et al. The forkhead transcription factor FoxO1 regulates proliferation and transdifferentiation of hepatic stellate cells. Gastroenterology 2007; 132: 1434-1446.
121. Kitamura T, Nakae J, Kitamura Y, et al. The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth. J Clin Invest 2002; 110: 1839-1847.
122. Hribal ML, Nakae J, Kitamura T, Shutter JR, Accili D. Regulation of insulin-like growth factor-dependent myoblast differentiation by Foxo forkhead transcription factors. J Cell Biol 2003; 162: 535-541.
123. Kamei Y, Miura S, Suzuki M, et al. Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, downregulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. J Biol Chem 2004; 279: 41114-41123.
124. Sandri M, Sandri C, Gilbert A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004; 117: 399-412.
125. Fukunaga K, Ishigami T, Kawano T. Transcriptional regulation of neuronal genes and its effect on neural functions: expression and function of forkhead transcription factors in neurons. J Pharmacol Sci 2005; 98: 205-211.
126. Gan L, Zheng W, Chabot JG, Unterman TG, Quirion R. Nuclear/cytoplasmic shuttling of the transcription factor FoxO1 is regulated by neurotrophic factors. J Neurochem 2005; 93: 1209-1219.
127. Rena G, Woods YL, Prescott AR, et al. Two novel phosphorylation sites on FKHR that are critical for its nuclear exclusion. EMBO J 2002; 21: 2263-2271.